Despite impressive progress with the recent approval of BTK and/or BCL2 inhibitors, the treatment of R/R CLL may represent an unmet need for patients carrying coexisting medical conditions which complicate these treatment options. The gene discussed is BTK; the disease is B-cell chronic lymphocytic leukemia.